Financial reports
10-K
2023 FY
Annual report
29 Mar 24
ARS
2022 FY
Annual report to shareholders
22 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-K/A
2022 FY
Annual report (amended)
26 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
Current reports
8-K
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
19 Apr 24
8-K
Other Events
15 Apr 24
8-K
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend
2 Apr 24
8-K
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
28 Mar 24
8-K
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders
21 Mar 24
8-K
Other Events
6 Mar 24
8-K
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
28 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Feb 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
19 Apr 24
424B5
Prospectus supplement for primary offering
18 Apr 24
424B3
Prospectus supplement
15 Apr 24
424B3
Prospectus supplement
15 Apr 24
424B5
Prospectus supplement for primary offering
28 Feb 24
424B5
Prospectus supplement for primary offering
26 Feb 24
424B3
Prospectus supplement
31 Aug 23
424B5
Prospectus supplement for primary offering
14 Aug 23
424B5
Prospectus supplement for primary offering
8 Jun 23
424B5
Prospectus supplement for primary offering
14 Mar 23
Proxies
DEFA14A
Additional proxy soliciting materials
20 Mar 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEF 14A
Definitive proxy
11 Mar 24
PRE 14A
Preliminary proxy
29 Dec 23
DEF 14A
Definitive proxy
22 Nov 23
DEF 14A
Definitive proxy
10 Jan 23
PRE 14A
Preliminary proxy
23 Dec 22
DEF 14A
Definitive proxy
17 Jun 22
DEFA14A
Additional proxy soliciting materials
16 Jun 22
Other
EFFECT
Notice of effectiveness
22 Jun 22
CORRESP
Correspondence with SEC
16 Jun 22
EFFECT
Notice of effectiveness
13 Jun 22
UPLOAD
Letter from SEC
13 Jun 22
EFFECT
Notice of effectiveness
4 May 22
EFFECT
Notice of effectiveness
4 May 22
EFFECT
Notice of effectiveness
20 Apr 22
CORRESP
Correspondence with SEC
18 Apr 22
UPLOAD
Letter from SEC
15 Apr 22
EFFECT
Notice of effectiveness
16 Sep 21
Ownership